Net Loss Per Share Attributable to Common Stockholders of BridgeBio (Tables)

12 Months Ended

Dec. 31, 2023

Earnings Per Share [Abstract]

Schedule of Common Stock Equivalents were Excluded from Computation of Diluted Net Loss per Share

The following common stock equivalents were excluded from the computation of diluted net loss per share attributable to common stockholders of BridgeBio, because including them would have been antidilutive:

	As of December 31,
	2023		2022		2021
Unvested RSAs		85,453		652,058		1,789,943
Unvested RSUs		8,942,813		4,108,642		3,537,719
Unvested performance-based RSUs		3,326		7,875		69,340
Unvested market-based RSUs		375,000		—		—
Common stock options issued and outstanding		12,332,442		11,637,861		12,141,756
Estimated shares issuable under performance-based milestone   compensation arrangements		4,865,250		19,201,212		13,959,588
Estimated shares issuable under the ESPP		75,889		217,660		172,927
Assumed conversion of 2027 Notes		12,878,305		12,878,305		12,878,305
Assumed conversion of 2029 Notes		7,702,988		7,702,988		7,702,988
		47,261,466		56,406,601		52,252,566